Xeris Biopharma Holdings Inc. Stock
A loss of -1.470% shows a downward development for Xeris Biopharma Holdings Inc..
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 7 € there is a slightly positive potential of 13.27% for Xeris Biopharma Holdings Inc. compared to the current price of 6.18 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -1.470% | -1.357% | -0.242% | 88.300% | 88.530% | 406.474% | 39.819% |
| Evolus Inc | -3.390% | 0.000% | -0.840% | -43.810% | -43.810% | -10.606% | 120.561% |
| Lexicon Pharmaceuticals Inc. | -3.200% | 4.724% | -15.832% | 40.811% | 40.811% | -40.647% | -62.746% |
| Krystal Biotech | -0.050% | 4.672% | 13.749% | 39.043% | 41.327% | 190.676% | - |
Comments
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat